Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1.

Thumbnail Image

Files

Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1.pdf (1.72 MB)

Embargo End Date

ICR Authors

Pierrat, Olivier
 Hahner, Tamas
 Burke, Rosemary
 Arwert, Esther
 Thapaliya, Arjun
 Salimraj, Ramya
 Van Montfort, Robert
 Raynaud, Florence
 Jones, Keith
 Newton, Gary
 Cheeseman, Matthew

Authors

Wilding, B
Pasqua, AE
E A Chessum, N
Pierrat, OA
Hahner, T
Tomlin, K
Shehu, E
Burke, R
Richards, GM
Whitton, B
Arwert, EN
Thapaliya, A
Salimraj, R
van Montfort, R
Skawinska, A
Hayes, A
Raynaud, F
Chopra, R
Jones, K
Newton, G
Cheeseman, MD

Document Type

Journal Article

Date

2021-06-15

Date Accepted

2021-04-13

Abstract

ERAP1 is a zinc-dependent M1-aminopeptidase that trims lipophilic amino acids from the N-terminus of peptides. Owing to its importance in the processing of antigens and regulation of the adaptive immune response, dysregulation of the highly polymorphic ERAP1 has been implicated in autoimmune disease and cancer. To test this hypothesis and establish the role of ERAP1 in these disease areas, high affinity, cell permeable and selective chemical probes are essential. DG013A 1, is a phosphinic acid tripeptide mimetic inhibitor with reported low nanomolar affinity for ERAP1. However, this chemotype is a privileged structure for binding to various metal-dependent peptidases and contains a highly charged phosphinic acid moiety, so it was unclear whether it would display the high selectivity and passive permeability required for a chemical probe. Therefore, we designed a new stereoselective route to synthesize a library of DG013A 1 analogues to determine the suitability of this compound as a cellular chemical probe to validate ERAP1 as a drug discovery target.

Citation

Bioorganic & medicinal chemistry letters, 2021, 42 pp. 128050 - ?

DOI

10.1016/j.bmcl.2021.128050

URI

https://repository.icr.ac.uk/handle/internal/4794

Rights

https://creativecommons.org/licenses/by/4.0

Source Title

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

ISSN

0960-894X

eISSN

1464-3405

Collections

Cancer Therapeutics
Structural Biology

Research Team

Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Medicinal Chemistry 3
Hit Discovery & Structural Design
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Medicinal Chemistry 3
Hit Discovery & Structural Design

Notes